fbpx

Mylan Antitrust EpiPen Settlement

Settlement Structure: Claims Made

Active: Open

Case Summary:

A group of entities—including Mylan NV, Mylan Specialty LP, Mylan Pharmaceuticals, Inc., Viatris, Inc., and Heather Bresch—has agreed to pay $246 million to settle class actions alleging that they violated antitrust, federal racketeering, and other laws, preventing effective competition and causing consumers and insurers to pay too much for EpiPen products. The products at issue included the EpiPen Auto-Injector, the EpiPen Jr. Auto-Injector, and any authorized generic versions of these products.

A group of Pfizer companies reached a settlement in this case at a previous date.

Docket Number:

2:17-md-02785-DDC-TJJ, MDL No. 2785

Company: Mylan NV

Filing Deadline: July 25, 2022

Class Period: August 24, 2011 to November 1, 2020

Objection Deadline: June 8, 2022

Final Approval Hearing: July 6, 2022

Proof of Purchase:

You do not have to submit documentation at this time, but the Settlement Administrator may ask for it later on. If you submitted a Claim Form in 2021 at the time of the settlement with the Pfizer defendants, you do not need to submit another form now.

Eligibility:

You may be eligible if you are a member of either of these groups:

- All persons and entities in the US who paid or provided reimbursement for some or all of the price of branded or authorized generic EpiPens, for consumption and not for resale, by themselves, their family members, insureds, plan participants, employees, or beneficiaries, at any time between August 24, 2011 and November 1, 2020; and
- All persons and entities in the Antitrust States who paid or provided reimbursement for some or all of the price of Branded EpiPens, at any time between January 28, 2013 and November 1, 2020, for the purpose of consumption and not resale, by themselves, their family members, insureds, plan participants, employees, or beneficiaries.

The Antitrust States are Alabama, California, Florida, Hawaii, Illinois, Kansas, Maine, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New York, North Carolina, Tennessee, and Utah.

Typical Settlement Amount:

The net settlement fund will be divided into two pools, one for individual consumers (20%) and one for third-party payors (80%). The funds will be distributed according to a proposed plan of allocation and distribution.

Total Settlement Amount: $264,000,000

Class Representative Proposed Incentive Fee:

Unknown

Law Firms:
Burns Charest LLP
Pritzker Levine LLP
Robbins Geller Rudman & Dowd

Claim Form: Mylan Antitrust EpiPen Settlement Claim Form

Case Name: In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices, and Antitrust Litigation

Settlement Website: Mylan Antitrust EpiPen Settlement Website

Claims Administrator:
AB Data, Ltd.

Claims Administrator Contact Information:

EpiPen Settlement
c/o A.B. Data, Ltd.
P.O. Box 173113
Milwaukee, WI 53217
info@EpiPenClassAction.com
877-221-7632

Tags: Antitrust, RICO laws, Requiring Consumer to Pay Higher Prices